Delivery Order SPE2DB25D3017-SPE2DB25FVKCU
- Not listed
- The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract worth $10,206.51 to Amerisourcebergen Drug Corp, a for-profit pharmaceutical distribution company, for the supply of EXJADE 500 MG TABLET 30S. This order is part of a larger indefinite delivery contract (IDC) with a potential value of $999,999,999.00, which serves as Amerisourcebergen Drug Corp's primary vehicle for delivering pharmaceutical products and medical supplies to DLA Troop Support Medical...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $20,176.86 firm fixed-price delivery order is for the supply of EXJADE 500 MG TABLET 30S, a specialty pharmaceutical product. The contract has an ultimate completion date of December 13, 2023. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves...
- This federal contract award is for the delivery of EXJADE 250 MG TABLET 30S, a specialty pharmaceutical product, to the Defense Logistics Agency (DLA). The $5,034.60 firm-fixed-price contract was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, on July 13, 2023, with a completion date of August 3, 2023. The contract is a delivery order placed under Amerisourcebergen's $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which provides a...
- The Defense Logistics Agency (DLA) awarded a firm-fixed-price delivery order contract to Amerisourcebergen Drug Corp's Corporate Office division, a major pharmaceutical supplier, to provide EXJADE 125 MG TABLET 30S for $6,761.12. This order is associated with Amerisourcebergen's $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, which enables the DLA to efficiently procure a comprehensive range of pharmaceutical products and medical supplies for the Department...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, a leading global pharmaceutical sourcing and distribution company. The $20,413.02 firm fixed price award is for the supply of EXJADE 500 MG TABLET 30S, a pharmaceutical product, to support DLA Troop Support Medical facilities. The contract has a completion date of February 8, 2024. Amerisourcebergen Drug Corp provides a range of pharmaceutical...
- The Defense Logistics Agency awarded a $6,761 firm fixed price delivery order to Amerisourcebergen Drug Corporation to supply 4562256402 EXJADE 125 MG TABLETS. The order is for 30 tablets to be delivered to a location in Conshohocken, Pennsylvania by October 6, 2023, with performance starting on September 15. Amerisourcebergen Corporation is the parent company of Amerisourcebergen Drug Corporation, which will serve as the prime contractor. No major subcontractors or set aside designations were...
- This is a delivery order federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of EXJADE 500 MG TABLET 30S, with a firm fixed price and a ceiling value of $4,006.76. The contract does not have a set-aside designation, indicating open competition. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with DLA Troop Support...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of EXJADE 500 MG TABLET 30S, a pharmaceutical product, with a ceiling value of $16,027.08 and a period of performance through July 16, 2025. The contract is a firm fixed-price delivery order, which is not designated as a set-aside. AmerisourceBergen Drug Corp holds a significant...
- This federal contract award, valued at $2,535.42, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of EXJADE 125 MG TABLET 30S, a prescription medication, to support military and government healthcare programs. Amerisourcebergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which holds a significant Indefinite Delivery Contract (IDC) with the DLA...
- This is a firm fixed price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, a leading pharmaceutical sourcing and distribution company. The $15,323.96 order is for the delivery of EXJADE 500 MG TABLET 30S, a pharmaceutical product. The contract has a completion date of January 24, 2024. No set-aside designation was used for this award. AmerisourceBergen Drug Corp has a strong track record of providing...
- SPE2DB25D3017Indefinite Delivery Contract
- SPE2DB25D3017-SPE2DB25FVKCUDelivery Order
The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $16,027.08 for Exjade 500 mg tablets (30-count units) on August 5, 2025, with an ultimate completion date of August 26, 2025. This firm fixed-price contract, which is not set-aside, represents a routine pharmaceutical supply requirement fulfilled by the prime contractor at its Conshohocken, Pennsylvania facility. The award is issued as a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026, which serves as the comprehensive global pharmaceutical support vehicle for military healthcare programs. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, maintains a substantial portfolio of federal medical procurement contracts with the Defense Logistics Agency, supplying a broad range of pharmaceutical products including specialty medications, brand-name and generic drugs, and medical supplies across multiple therapeutic domains. The company's demonstrated capability to fulfill federal requirements through open competition aligns with DLA's strategy to ensure reliable pharmaceutical supply chains for Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. This delivery order for Exjade, a chelation therapy medication, reflects routine execution under the existing prime vendor contract framework supporting military medical operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $16.0k | 8/5/25 |